- STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDBiotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.
- STAT+: CMS evaluates one year of health tech progress, announces eight new pledge categoriesOne year after launching the CMS Health Tech Ecosystem, officials convened in D.C. to celebrate the Trump administration modernizing health technology.